

**INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY
AND BIO SCIENCES****IMPACT FACTOR 4.018*******ICV 6.16*******Pharmaceutical Sciences****Research Article.....!!!****“FORMULATION AND EVALUATION OF NANOPARTICLES LOADED
TRANSDERMAL DRUGDELIVERY SYSTEM OF LISINOPRIL”****Korlapalli Manasa¹ Dr Darshanam VijayKumar² Madireddy Divya³ Ravi Maloth⁴ Md Saleem⁵**¹Ms Pharmaceuticals, ²Associate Professor Department Of Pharmaceutics, Swami Vivekananda Institute Of Pharmaceutical Sciences, Vangapally, Yadagirigutta, Yadadri-Bhongir, Telangana 508115.³ CQA - Formulations in Hetero Drugs Limited in Hyderabad.T.S.^{4,5}. Assistant Professor, Moonray institute of pharmaceutical Sciences, Raikal, Shadnagar, RangaReddy, TS.509202.**KEYWORDS:**

Nanoparticles; Lisinopril ;
Compritrol 888 ATO; Span 60;
Tween 80; HPMC-E50;
transdermal.

FOR CORRESPONDENCE:**Korlapalli Manasa *****ADDRESS:**

Associate Professor Department
Of Pharmaceutics, Swami
Vivekananda Institute Of
Pharmaceutical Sciences,
Vangapally, Yadagirigutta,
Yadadri-Bhongir, Telangana
508115.

ABSTRACT

Lisinopril is an Angiotensin Converting Enzyme (ACE) inhibitor, it belongs to the BCS class II. The current study encompasses the formulation of novel nanoparticles loaded transdermal patches of Lisinopril with the aid of Box Behnken Design. Pre-formulation studies such as identification of the drug by FT-IR, the estimation of the drug by UV spectroscopy and the melting point determination were performed. The nanoparticles were formulated by solvent emulsification evaporation method using Compritrol 888 ATO as lipid, Span 60 and Tween 80 as surfactants to improve the physicochemical properties of Lisinopril . The prepared nanoparticles were evaluated for particle size, polydispersity index, zeta potential, entrapment efficiency, drug content and in-vitro drug release studies and the evaluated data was used to carry out numerical optimization to obtain the best formulation with the optimum concentration of excipients. The optimized concentration for independent variables Lisinopril (X1), Compritrol 888 ATO (X2), and Span 60 (X3) were found to be 75mg, 2000mg, and 60mg respectively, with the desirability of 0.916. The optimized formulation of Nanoparticles were then loaded into a HPMC-E50-based transdermal patch by solvent casting method to overcome the restricted bioavailability of Lisinopril . The thickness, folding endurance, weight uniformity, drug content and in-vitro drug release of the patch were evaluated. The drug release from the patch was found to be greater than the release from the solid lipid nanoparticles. The reason could be due to the intimate contact of the patch to the skin and the use of a penetration enhancer in the patch formulation. In conclusion, the results obtained suggest that a patch formulation containing nanoparticulate system is a potentially promising formulation for the efficient delivery of Lisinopril through skin.

INTRODUCTION:

Lisinopril is a potent anti-hypertensive drug. It is an ACE inhibitor and a class II drug with limited solubility which represent a rate-limiting step in its absorption thus, Lisinopril faces a decreased bioavailability (28- 35%) which could limit its therapeutic activity^[1].

Nanoparticles (NPs) are solid colloidal particles ranging from 10 to 1000nm in size, where the active pharmaceutical ingredient(s) are dissolved, entrapped, encapsulated, adsorbed, or attached to a nanoparticle matrix. Nanoparticles have special characteristics such as small particle size, large surface areas and the capability of changing their surface properties makes them good and advantageous candidates for drug delivery compared to other drug delivery systems.

In recent years nanotechnology has offered a suitable means for delivery of small molecular weight drugs as well as macromolecules such as proteins, peptides or genes to cells and prevent them against enzymatic degradation. Nanoparticles as drug delivery systems are biodegradable, non-toxic, and capable of being stored for longer periods as they are more stable.^[2]

Transdermal drug delivery system delivers the drugs through the skin portal to systemic circulation at a predetermined rate and maintains clinically the effective concentrations over a prolonged period of time. The main merits of transdermal drug delivery are non-invasiveness, sustained release, self-administration and enhanced therapeutic efficacy and specificity to the target. Stratum corneum acts as a natural barrier and limits the transport of drug through the skin. Nanocarriers are able to alter the stratum corneum due to their shape, size, surface charges and show an enormous potential for transdermal delivery. The nanocarriers can be classified into polymer based and lipid-based delivery carriers. The lipid based nanocarriers show great properties in terms of safety, physical stability, biocompatibility, efficacy scale-up, ease of preparation, better entrapment of lipid soluble drugs, prolonged drug release of formulation. These may improve the solubility and bioavailability of active pharmaceutical ingredients (API), guard these compounds from external objects such as light or oxygen thereby facilitating drug targeting. Since Lisinopril is a lipophilic drug with low aqueous solubility, solid lipid nanocarriers were selected for this study^[3]. Myriad studies have shown Lisinopril's distribution and bioavailability have been improved employing nanoparticle formulations for the drug by using different polymers and lipids[4–7].

On this basis, the aim of this study is to formulate and evaluate solid lipid nanoparticles of Lisinopril using Compritol 888 ATO as lipid, Span 60 and Tween 80 as surfactants and to load the formulated nanoparticles into a HPMC-E50 based transdermal patch in order to improve its bioavailability by by-passing its extensive first pass metabolism associated with its oral administration, also to improve its permeation through the skin by the use of nanocarriers.

Materials and Methods:***Material***

Lisinopril was purchased from Triveni Interchem Pvt.Ltd, Gujarat, Compritol 888 ATO was obtained as gift sample from Gattefosse India Pvt.Ltd, Mumbai, Span 60 and Hydroxyl Propyl Methyl Cellulose (E50) were obtained from Micro Lab, Mumbai, Tween 80 from Merck Ltd, Mumbai and all other chemicals used were of analytical grade.

Methods**Pre-formulation studies: Determination of UV absorption maxima of Lisinopril :**

To determine the wavelength of maximum absorption (λ_{max}), Lisinopril standard solution (10 μ g/ml) was prepared in Phosphate buffer solution pH 7.4 containing 10% methanol, scanned in UV wavelength range of 200-400nm using phosphate buffer pH 7.4 as a blank. The absorption maxima obtained in the graph was considered as λ_{max} for the pure drug solution in the respective buffer.

Preparation of calibration curve of Lisinopril in pH 7.4 phosphate buffer

Stock-1 solution: 100mg of Lisinopril was weighed accurately and dissolved in methanol using a 100ml volumetric flask(1000 μ g/ml).

Stock-2 solution: 2.5ml from stock-1 solution was pipetted out and diluted to 25ml with phosphate buffer pH 7.4 (100 μ g/ml). From this solution 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 2.1 and 2.4ml was pipetted out and diluted to 10 ml using pH 7.4 phosphate buffer to get aliquots of 3, 6, 9, 12, 15, 18, 21 and 24 μ g/ml respectively. pH 7.4 phosphate buffer was used as blank solution. The absorbance was measured at 209nm using UV-Visible Spectrophotometer. The standard graph was repeated three times (n=3). The mean data was plotted by taking concentration on X-axis and absorbance on Y-axis.

Identification of drug by FTIR

Weighed amount of drug (Lisinopril) was mixed with IR grade potassium bromide KBr (1:10) and compressed under 10-tons pressure in a hydraulic press to form a transparent pellet. The pellet was scanned by IR spectrophotometer over a frequency of 4000 cm^{-1} to 400 cm^{-1} range.^[1]

Drug-excipients compatibility study

Physical mixture of drug (Lisinopril) and excipients (Compritol 888 ATO, Span 60, Tween 80, HPMC-E50) was mixed with IR grade KBr (1:10) and compressed under 10-ton pressure in a hydraulic press to form a transparent pellet. The pellet was scanned by IR spectrophotometer over a frequency of 4000 cm^{-1} to 400 cm^{-1} range.

Melting point determination

Fine powder of Lisinopril was filled in glass capillary tube one end of which was previously sealed. The capillary tube was inserted into the melting point apparatus which contained liquid paraffin and heated.

The temperature t which the drug began to melt was observed by using the thermometer which was already immersed into the liquid paraffin in the apparatus.

Formulation studies:

Preparation of Nanoparticles:

Compritol was selected as the solid lipid for preparing the SLN. The lipid phase containing Compritol ATO 888,

and Span 60 was melted to 80 . The Lisinopril was dissolved in methanol and added to the melted lipid phase. The

aqueous phase was prepared by dissolving the Tween 80 in distilled water and heated it up to the same temperature of the lipid phase. The lipid phase was poured into the aqueous phase and stirred for 6 hours using magnetic stirrer until all the methanol evaporated. Nanoparticles thus produced were evaluated for different parameters such as particle size, zeta potential, polydispersity index, entrapment efficiency, drug content and drug release.^[8-9]

Design of experiment: Use of experimental design allows for simultaneous testing of factors and precludes the use of a large number of independent runs. Systematic optimization procedures are carried out by selecting an objective function, finding the contributing factor(s) and investigating the relationship between response(s) and factor(s) by the response surface methodology.^[10] The Objective for the present study was maximizing entrapment efficiency, while minimizing particle size. Box–Behnken design was used to statistically optimize formulation parameters and evaluate the main effects, interaction effects, and quadratic effects of the lipids, surfactant, and drug on the responses listed above. The three-factor two-level design was used to explore quadratic response surfaces and construct second-order polynomial models using Design Expert software version 13. The Box-Behnken design was constructed where the amounts of COMPRITOL 888 ATO, SPAN 60 and LISINOPRIL were selected as independent variables. The levels of the 3 variables were selected based on preliminary trials carried out before implementing the experimental design.

Table 1: Factors of Box Behnken Design

Factors	Name	Units	Low	High
A	COMPRITOL 888 ATO	MG	1000	2000
B	SPAN 60	MG	30	60

C	TWEEN 80	MG	75	150
---	----------	----	----	-----

Table 2: Formulation chart of Lisinopril loaded nanoparticles (F1 to F13):

FormulationCode	Lisinopril (mg)	Compritol 888AT	Span 60(mg)	Tween 80(mg)	Distilled water
	150	1000	45	45	30
	112.5	2000	30	45	30
	112.5	1500	45	45	30
	75	1000	45	45	30
	150	1500	30	45	30
	75	1500	60	45	30
	112.5	1000	60	45	30
	150	2000	45	45	30
	112.5	2000	60	45	30
	150	1500	60	45	30
	112.5	1000	30	45	30
	75	2000	45	45	30
	75	1500	30	45	30

Box–Behnken design was specifically selected, because it requires fewer runs than a central composite design, with same number of variables. A design matrix that consists of 13 experimental runs was constructed. All the batches were evaluated, and different polynomial equations were derived for particle size, zeta potential, % entrapment efficiency and % drug release. The statistical analysis of the factorial design batches was performed by ANOVA using Design-Expert software. A statistical model incorporating interactive and polynomial terms were used to evaluate the response.

$$Y = b_0 + b_1 A + b_2 B + b_3 AB + b_4 A^2 + b_5 B^2$$

In this equation, Y is the response, and b₀ is the arithmetic mean response of 13 runs. b₁, b₂, b₃, b₄, and b₅ are the estimated coefficient for the factors A and B. The polynomial equations were generated by linear multiple regression that quantitatively explain the effect of the different variables on the attributes.^[11]

Evaluation of Nanoparticles

Particle size and Polydispersity index

The Particle size of nanoparticles plays an especially significant role in drug permeation through the skin. Polydispersity index describes the particle size distribution of nanoparticles. It helps to know the average uniformity of particles size of the sample. High poly dispersity index value describes the high degree of non-uniformity of a distribution of the particles in the nanoparticle formulation. By using the dynamic light scattering (DLS) technology, the average particle size and the poly dispersity index were

evaluated in Horiba Scientific (Nano-partica) SZ-100 at an angle of 90° at 25 °C. For the measurement, 1ml of the sample diluted to 10ml with double distilled water and sonicated for 15 minutes and vortexed, kept in polystyrene cuvettes for the evaluation of the particle size and poly dispersity index (n=3). [1]

Zeta potential

Zeta Potential (ZP) is the electric charge on the particle surface. It helps to predict the storage stability of the colloidal dispersion. At higher zeta potential, less particle aggregation occurs due to electrical repulsions. Zeta potential was measured using Horiba Scientific (Nano-partica) SZ-100. 1ml of formulated SLNs was diluted to 10ml with double distilled water and sonicated for 15 minutes [12]. Then the sample was transferred into the cuvette which contains electrode and kept inside the instrument and zeta potential of sample measured (n=3).

Drug content

Formulation equivalent to 5mg of drug was taken, 1ml of chloroform was added and then the volume was made up to 10ml with methanol. The resultant solution was then centrifuged at 6000 RPM for 1 hour after which the supernatant layer was filtered. 1ml was taken from the filtered supernatant and the volume made up to 10ml [12]. Absorbance of the sample was then measured at 209nm, and the drug content determined using the following formula:

Drug Content in mg = absorbance/slope *dilution factor*1/1000.

Entrapment efficiency

The Entrapment efficiency of prepared sample was determined by measuring the concentration of the drug in the dispersion medium. The free drug Lisinopril was determined by adding formulation equivalent to 5mg of Lisinopril in a volumetric flask and the volume was made up to 10ml with ethanol and then transferred to centrifuge tubes and then this dispersion was centrifuged at 6000 rpm for 1 hour. The supernatant was filtered and diluted with buffer and measured spectrophotometrically at 209nm (n=3). The amount of drug in supernatant (W_{free}) was then subtracted from the total amount of drug of the preparation (W_{total}) [1]. The entrapment efficiency was calculated using the following equation.

$$\text{Entrapment Efficacy (EE\%)} = \frac{(W_{total} - W_{free})}{W_{total}} \times 100$$

Diffusion study of Lisinopril from SLNs

In vitro release of Lisinopril from nanoparticle formulation was studied using dialysis bag method in phosphate buffer pH 7.4. The dialysis bag procured from HIMEDIA having molecular weight cut off between 12000 to 14000 Daltons and pore size is 2.4nm. 7cm of the dialysis bag was soaked in

distilled water for 24 hrs before the experiment. One end of the bag was tied with a thread and Lisinopril nanoparticles sample (equivalent to 5mg of drug) was added into the dialysis bag from another end and tied to the burette stand with a thread. The dialysis bag containing nanoparticle sample was placed in 1000ml of dissolution medium (glass rod was used to immerse the dialysis bag in order to avoid the floating of the bag) which was continuously stirred at 100 rpm at 37 °C using magnetic stirrer. Aliquots (5ml) were withdrawn at predetermined time intervals (1 hour) and the same volume of fresh dissolution medium was added to maintain a sink condition. The samples withdrawn were analyzed spectrophotometrically at 209nm (n=3).^[11]

Preparation of Transdermal Patch of Lisinopril

The matrix-type transdermal patch containing Lisinopril was prepared by solvent casting method using hydroxyl propyl methyl cellulose (HPMC E50) polymer. The total weight of polymer used was 350mg. Accurately weighed amount of polymer was dissolved in distilled water with continuous stirring. Polyethylene glycol 400 was added as plasticizer and dimethyl sulfoxide as penetration enhancer.^[13] Both plasticizer and penetration enhancer were used at 10% w/w of total polymeric concentration. An area of 4cm² was desired to contain 5mg of Lisinopril. Hence, the film casting area of 25cm² would require the quantity of nanoparticle formulation equivalent to 31.25mg of drug. The nanoparticle formulation was added to polymer solution. The resultant formulation was sonicated for 5 minutes to remove air bubbles. The solution was then poured into a Petri dish using aluminum foil as backing membrane. The solvent was then allowed to dry in the hot air oven at a temperature of 45°C for 24 hours. The patch obtained was carefully peeled off and evaluated.

Table 3: Formulation chart of Lisinopril nanoparticles loaded transdermal patch.

s/no	Ingredients	Quantities
1	Lisinopril (mg)	31.25
2	HPMC-E50 (mg)	350
3	Polyethylene glycol(mg) (10% w/w of total polymer weight)	35
4	Dimethyl sulfoxidemg (10% w/w of total polymer weight)	35
5	Distilled water (ml)	20

Evaluation of patch:^[14]

Physical appearance: The patch was physically inspected for color, clarity, uniformity, flexibility and smoothness.

Determination of thickness: Vernier calipers were used to determine the thickness of randomly selected patches. The patch was measured at different points and the average of three readings was taken.

Folding endurance: Folding endurance of patch was measured manually by folding the patch at one place a number of times till it breaks. This gives a value of folding endurance.

Weight variation: Weight variation was studied by individually weighing 3 randomly selected

patches. The mean value was calculated.

Drug content: A prepared patch was added to 10ml methanol and stirred vigorously for 2 hours using a magnetic stirrer. The solution was Filtered and 1ml was diluted to 10ml with pH 7.4 phosphate buffer and Lisinopril was estimated spectrophotometrically at wavelength of 209 nm.

Diffusion study of Patch:

In- vitro drug release studies were performed by a Franz diffusion cell. Drug release from patch formulation was compared with nanoparticle formulation. Dialysis membrane has molecular weight cut off between 12000 to 14000 Da and having pore size 2.4 nm (HI MEDIA) was employed for the determination of drug diffusion. The receptor compartment of the diffusion cell was filled with phosphate buffer pH 7.4 and the patch or the nanoparticle formulation was placed in the donor compartment. The recipient compartment was constantly and continuously stirred using magnetic bead and the temperature was maintained at $37 \pm 0.5^\circ\text{C}$. The samples were withdrawn at time intervals of 1 hour and analyzed for drug content spectrophotometrically.

Results and Discussion

Pre-formulation studies:

Determination of UV absorption maxima of Lisinopril :

Lisinopril standard solution ($10\mu\text{g/ml}$) was scanned in UV-Spectrophotometer with a wavelength range of 200- 400nm. The absorption maxima were found to be 209nm. So, the standard curve was developed at this wavelength.

Preparation of Calibration Curve of Lisinopril in PH 7.4 phosphate buffer:

The calibration curve was linear between 3-24 $\mu\text{g/ml}$ concentration range. The standard calibration curve of Lisinopril was constructed in pH 7.4 phosphate buffer by plotting mean absorbance vs concentration at 209nm ($n=3$). The R^2 and slope values were found to be 0.999 and 0.0366 respectively.

Identification of drug by FTIR and Drug-excipients compatibility study:




Fig 1: FTIR spectra of Lisinopril .




Fig 2: FTIR spectra of Lisinopril + Compritol + Span 60 + Tween 80 + HPMC. Identification study was performed using FTIR spectrophotometer. The characteristic absorbance peaks of Lisinopril were obtained at different wave numbers. The peaks obtained in the spectra of pure drug correlates with the peaks of official spectrum of standard reference which confirms the purity of the drug. The compatibility study was carried out using FTIR spectrophotometer. The FTIR spectrum of pure drug and physical mixture of drug and excipient was studied. The FTIR spectra of Lisinopril indicates the characteristic peaks at 3280 cm^{-1} due to N-H Stretching, at 3066 cm^{-1} due to O-H Stretching, at 2934 cm^{-1} due to C-H Stretching, at 1773 cm^{-1} due to C=O Stretching, at 1278 cm^{-1} due to C-N Stretching and at 1228 cm^{-1} due to C-O Stretching. It was observed that there is no chemical interaction between the drug and the excipients used in the formulations as indicated by the presence of all characteristic peaks of the drug which indicates that the drug was compatible with the formulation components.

Melting Point

The melting point of Lisinopril was determined by capillary method. The melting point was found to be 109°C . The melting point of Lisinopril is $105\text{-}112^\circ\text{C}$ as per literature thus indicating the purity of the drug.^[1]

Evaluation of Nanoparticles of Lisinopril

Table 4: Results of evaluated parameters of Lisinopril Nanoparticles.

Formulation	Particle Size (nm)	Zeta Potentia (mv)	Drug Content (%)	Entrapment Efficiency (%)	In-vitro drug Release at 6 th hour (%)
F1	106.7	34.5	95.8	52.0	91.6
F2	149.2	24.0	95.6	89.2	57.1
F3	99.7	30.5	93.6	77.9	82.9
F4	33.9	30.6	99.0	80.0	88.8
F5	180	27.4	94.2	63.8	81.9
F6	37.3	-31.4	94.0	92.0	90.5
F7	18.9	44.1	88.8	65.2	98.3
F8	187.4	23.9	94.2	77.7	80.3

F9	31.5	14.8	93.0	87.2	81.1
F10	89.3	15.4	95.0	66.9	91.7
F11	127.7	-38.7	90.4	66.6	86.2
F12	79.7	22.0	96.2	92.8	77.3
F13	160.6	31.1	91.6	92.3	81.8

Particle size:

The particle size of obtained nanoparticles ranged from 31.5nm to 180nm.

The mean particle size of colloidal particles is an important characteristic of solid lipid nanoparticles (SLNs) which is measured using Nanoparticle analyzer Horiba SZ-100. Mean particle size and polydispersity index of the nanoparticles were obtained. The results showed that all the SLNs are in the nano-sized range and had low polydispersity index which indicates relative narrow size distribution. Sizes ranged from 18.9nm to 180.7nm and the polydispersity index ranged from 0.3 to 3.0 respectively. The ANOVA (Analysis of Variance) for linear model was used to analyze the particle size of the formulated nanoparticles. The P value and R² value was found to be 0.0003 and 0.8631 respectively, showing the model is significant.

The final equation in terms of Coded Factors.

$$\text{Particle size} = +100.08 + 32.01 A + 19.55 B - 55.06 C$$

Were,

A = Lisinopril , B = Compritol 888 ATO and C = Span 60

According to the coded factor equation of particle size, the Lisinopril has a positive effect on particle size. As concentration of Lisinopril increases, particle size also increases and vice-versa. Compritol 888 ATO has the same effect as Lisinopril on particle size. Whereas the concentration of Span 60 shows a negative effect on particle size, as concentration of Span 60 increases, the particle size decreases. This is because higher surfactant concentrations effectively stabilized the particles by forming a steric barrier on the particle surface and thereby protect smaller particles and prevent their coalescence into bigger ones. High surfactant concentrations might decrease particle size due to effective reduction in interfacial tension between the aqueous and lipid phases leading to formation of emulsion droplets of smaller size.^[15] A possible explanation for the influence of Compritol on SLNs may be due to its high melting point (65-77 °C) and the long chain hydrocarbon chain of Behenic acid (C22) which represents 85% of the acids esterifying glycerol in Compritol. High melting point results in an increase in viscosity and leads to an insufficient homogenization which causes an inefficient reduction of the particle sizes. Moreover, the long chain hydrocarbons of Behenic acid in Compritol result in bulkier molecules that are less susceptible to packaging into small particles.^[16] The type and concentration of surfactants used are helpful in preventing aggregation of the particles, thus maintaining a low polydispersity index.




Fig.3: 3-D graph of particle size.

Zeta potential

The zeta potential of obtained nanoparticles ranged from +24.0mv to +44.1mv. No model was found to be significant for statistical evaluation of zeta potential.

The ANOVA (Analysis of Variance) for 2FI model was used to analyze the zeta potential of the prepared nanoparticles. The p-value and R^2 value were found to be 0.6329 and 0.4281 respectively, indicating the model was not significant.

According to the DLVO theory, a system is regarded as stable if the electrostatic repulsion dominates the attractive van der Waals forces. The particles have to overcome an energy barrier of electrostatic repulsion to approach closely and form agglomerates. If their velocity or kinetic energy is high enough, they will collide. Higher temperatures as well as light increase the kinetic energy of a system, in combination with a reduced zeta potential this leads to SLN aggregation.^[17] A zeta potential value in the range of -30 mV to +30 mV is generally considered as the standard value in which particles show the sufficient repulsive force to attain better physical colloidal stability.^[18] Except a few formulations (F1,F7,F11), all formulations showed zeta potential between -30mv to +30mv.

Entrapment Efficiency

The results showed that the entrapment efficiency of Lisinopril loaded solid lipid nanoparticles ranged from 52 to 92.8%. ANOVA for the linear model of entrapment efficiency showed the p-value of <0.0001 and an R^2 value of 0.9585 indicating the model is significant.

Final equation in terms of Coded Factors:

$$\text{Entrapment Efficiency} = +77.20 - 12.09 A + 10.39 B - 0.0750 C$$




Fig.4: 3-D graph of entrapment efficiency

According to this equation, an increase in Lisinopril concentration decreases entrapment efficiency while Compritol 888 ATO has a positive effect on entrapment efficiency. As concentration of Compritol increases, entrapment efficiency increases. Increased concentration of compritol increases the entrapment efficiency this is because compritol is a complex lipid made of mono-, di- and triglycerides which form fewer perfect crystals with many imperfections offering space to accommodate the drugs thereby increasing the entrapment efficiency. Also, the high entrapment efficiency observed with compritol can be attributed to the high hydrophobicity due to long chain fatty acids attached to the triglycerides resulting in the increased accommodation of lipophilic drugs.^{[17][19-20]} Span 60 has a negative effect on entrapment efficiency. As concentration of Span 60 increases, the entrapment efficiency decreases. High surfactant levels in the external phase might increase the partition of the drug from the internal to the external phase of the medium. This increased partition is due to the increased solubilization of the drug in the external aqueous phase such that more volumes of the drug can disperse and dissolve in it.^{[15][21]}

In-vitro drug release study using dialysis membrane

In-vitro drug release of Lisinopril SLNs was performed in Phosphate buffer (pH 7.4) using a dialysis membrane technique. The % drug release at 6th hour from the prepared formulation is given in the table 4. **ANOVA** (Analysis of Variance) for the linear model of in-vitro drug release showed the *p*-value and *R*² value of drug release at 6th hour are 0.0011 and 0.8185 respectively.

Equation in Terms of Coded Factor:

$$\text{Drug release at 6}^{\text{th}} \text{ hour} = +83.81 + 0.8875 A - 8.64 B + 6.83 C$$




Fig.5: 3-D graph of in-vitro drug release.

According to the equations above, Lisinopril shows a positive effect on the drug release. As the concentration of Lisinopril increases, the drug release increases. Compritol 888 ATO shows a negative effect. As the concentration of Compritol increases, the drug release decreases. Increased concentration of lipid results in higher drug entrapment and significantly prolong drug release. This may be related to the triglycerides with lipophilic long chain fatty acids which prolong the release of lipophilic drug. Increase in lipid concentration can also lead to prolonged drug release due to reduced drug partition in the outer phase and consequently its release in the receiver media. In other words, as the lipid concentration in the SLN preparation was increased, the thickness of the lipid coating increased thereby increasing the length of diffusion resulting in decrease in the drug release. Compritol ATO 888 produces less ordered lipid crystals leading to lower drug expulsion from the imperfect lattice, contributing to the prolonged release of the lipophilic drug.

Fig 6: In-vitro drug release of Lisinopril solid lipid nanoparticles (F1, F4, F7 and F11):




Fig 7: In-vitro drug release of Lisinopril solid lipid nanoparticles (F3, F5, F6, F10 and F13)




Fig 8: In-vitro drug release of Lisinopril solid lipid nanoparticles (F2, F8, F9 and F12)

The concentration of the lipid, Compritol 888 ATO was kept constant at 1000mg while concentration of Span 60 was varied (Fig 6). Similarly the lipid was kept constant at 1500mg in Fig 7 and at 2000 mg in fig 8 respectively. It was observed that as the concentration of Span 60 increased, %drug release increased.

Increasing the concentration of Span 60 increases drug release from the SLNs. Increased concentration of surfactant increased in-vitro drug release due to decreased particle size hence increased surface area with improved solubilization in the recipient media. The fast or rapid release and higher release efficiency noticed at higher surfactant concentration could be explained by the partitioning effects of the drug between the melted lipid phase and the aqueous surfactant phase during particle production. During particle production by the solvent emulsification technique, drug partitions from the liquid oil phase to the aqueous water phase. The amount of drug partitioning to the water phase will increase with the increase of the drug solubility in the water phase, which means with increasing temperature of the aqueous phase and increasing surfactant concentration. The higher the temperature and surfactant concentration, the greater is the solubility of the drug in the water phase so the amount of drug in the outer shell increased and released in a relatively rapid way. Surfactants can increase the drug release due to a high HLB value and its ability to reduce the interfacial tension between SLN and the dissolution media and decrease the aggregation of particles and enhances the dissolution of drug.^[15]

Table 5: In-vitro drug release parameters of formulations F1-F13

Formulation	Zero	First	Higuchi plot	kosemeyerPeppas		Mechanism Of drug
	R ²	R ²	R ²	R ²	n value	
F1	0.985	0.821	0.979	0.983	0.626	Non-Fickian
F2	0.985	0.818	0.979	0.972	0.733	Non-Fickian
F3	0.983	0.852	0.989	0.970	0.633	Non-Fickian
F4	0.982	0.919	0.992	0.969	0.608	Non-Fickian
F5	0.975	0.813	0.997	0.967	0.627	Non-Fickian
F6	0.978	0.756	0.989	0.869	0.732	Non-Fickian
F7	0.970	0.803	0.996	0.966	0.663	Non-Fickian
F8	0.974	0.894	0.997	0.965	0.641	Non-Fickian
F9	0.984	0.962	0.980	0.972	0.763	Non-Fickian
F10	0.972	0.797	0.997	0.969	0.720	Non-Fickian
F11	0.996	0.776	0.982	0.986	0.678	Non-Fickian
F12	0.972	0.688	0.982	0.963	0.666	Non-Fickian
F13	0.996	0.675	0.996	0.967	0.677	Non-Fickian

Numerical Optimization

Numerical optimization technique was carried out using Design Expert software version 13 to obtain optimal concentrations of independent variables in order to minimize particle size, to maximize

entrapment efficiency and to enhance the % drug release which are basis for selecting an optimized formulation. The optimized formulation suggested the composition as follows. Lisinopril (X1) = 75mg, compritol 888 ATO (X2) = 2000mg and Span 60 (X3) = 60mg with a desirability of 0.916. With these concentrations, the suggested responses were 32.55nm for particle size, 12.89mv for zeta potential, 99% for entrapment efficiency, 48.6% for drug release at 6th hour and 70.8% for drug release at 6th hour. The practical results of the optimized formulation were closely related to the predicted results. The optimized formulation was loaded into the transdermal patch.

Evaluation of Lisinopril Nanoparticles loaded Transdermal Patch:

Table 6: Evaluation of Lisinopril SLNs loaded transdermal patch:

Formulation	Thickness(mm)	Folding endurance	Weight Variation (mg)	Drug Content(%)
Patch	0.099±0.005	189±0.03	96.90±0.002	98.90

Thickness: The thickness of the patch was found to be 0.099±0.05mm.

Folding Endurance: The folding endurance of the patch was found to be 189±0.03 indicating that the patch did not break easily and maintained its integrity with general skin folding when applied and it had the ability to withstand rupture.

Weight uniformity: The patch was subjected to weight variation by individually weighing dried patches of 4.0 cm². The weight variation was found to be 96.90±0.002mg.

Drug Content:

The drug content of the patch was found to be 98.90%.

The thickness and weight of the patch depends on the concentration of polymer used in the formulation. An excessive increase in the concentration of the polymer could lead to an increase in weight and thickness of the patch. However, high concentration of polymer decreases the drug loading capacity of the patch, hence, the concentration of polymer used has to be carefully considered.

Diffusion study of Patch:

The drug release from the patches was compared to the release of the drug from the SLNs. Release from the patches was found to be more compared to that from the SLNs. The drug release from the patch followed zero order kinetics and the mechanism of release was non-Fickian. The release of drug from the patch was found to be greater than the release from the nanoparticle formulation. The reasons could be as follows:

1. The intimate contact the patch has with the diffusion membrane aids the natural diffusion of the drug into the diffusion media.
2. The use of DMSO as penetration enhancer in the patch formulation could have increased diffusion of drug through the diffusion membrane.

So it can be concluded that the drug release from patch was comparatively more than solid lipid

nanoparticles and follows zero order release kinetics and non fickian diffusion mechanism.

Fig.9: % Drug release from Lisinopril loaded SLNs in comparison to the % drug release from SLNs loaded patch.

Table 7: Kinetic values of drug diffusion from patch formulation:

Formulation Code	Zero order Plo	First order pld	Higuchi plot	Kosermeyer Peppaspld		Mechanism of drug Release
	R ²	R ²	R ²	R ²	n-value	
patch	0.988	0.766	0.920	0.878	0.640	Non-Fickian

REFERENCES:

1. Ekambaram P, Abdul Hasan Sathali A. Formulation and evaluation of solid lipid nanoparticles of Lisinopril . Journal of Young Pharmacists. 2011;3(3):216–20.
2. B.Ramu et al. Formulation and Evaluation of Colon Specific Drug Delivery of Press Coated Lansoprazole Tablets Indo American Journal of Pharm Research.2015;5(04).
3. Wang, FY., Chen, Y., Huang, YY. *et al.* Transdermal drug delivery systems for fighting common viral infectious diseases. *Drug Deliv. and Transl. Res.* 11, 1498–1508 (2021).
4. Vakhariya RR, Salunkhe VR, Randive DS, Bhutkar MA, Bhinge SD. Design, Development and Optimization of Lisinopril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method. *Nanoscience & Nanotechnology-Asia.* 2021;11(1):42–52.
5. Chadha R, Bhandari S, Kataria D, Gupta S. Exploring Lecithin/Chitosan Nanoparticles of Lisinopril for Improved Antihypertensive Efficacy. *J Nanopharm Drug Deliv.* 2013 ;1(2):173–81.
6. Pereira A, Gadad AP, Patil AS, Dandagi PM. Development and bioavailability assessment of Lisinopril nanoparticle formulation. *Indian Journal of Pharmaceutical Education and Research.* 2019;53(4): S587–95.
7. Ramesh Y, Sireesha V. Transdermal Patch Of Lisinopril Loaded Chitosan Nanoparticles Dispersed InCarbopol Gel. *Journal of Drug Delivery and Therapeutics.* 2017;7(6):56-65.
8. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences.* 2009;71(4):349–58.
9. Abdelbary, G., Fahmy, R.H. Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization. *AAPS PharmSciTech.* 2009; 10: 211–219.
10. Kalam, M. A., Sultana, Y., Ali, A., Aqil, M., Mishra, A. K., Aljuffali, I. A., & Alshamsan, A. (2013). Part I: Development and optimization of solid-lipid nanoparticles using Box–Behnken statistical design for ocular delivery of gatifloxacin. *Journal of Biomedical Materials Research Part A,101A* (6), 1813-1827.
11. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments.” Part II: Retrospect and prospects. *Critical Reviews in Therapeutic Drug Carrier Systems.* 2005;22(3):215–93.

12. Ekambaram P, Abdul Hasan Sathali A. Formulation and evaluation of solid lipid nanoparticles of Lisinopril . *Journal of Young Pharmacists*. 2011;3(3):216–20.
13. Bhanja S, Rawat BS, Sudhakar M, Panigrahi B. Design, Development and Evaluation of Transdermal Patches of Lisinopril . *International Journal of Advances in Pharmacy, Biology and Chemistry*. 2014;3(2):352–60.
14. Shymaa Hatem, Seham A. Elkheshen, Amany O. Kamel, Maha Nasr, Noha H. Moftah, Maha H Ragai, Reham S. Elezaby & Nada M. El Hoffy (2022) Functionalized chitosan nanoparticles for cutaneous delivery of a skin whitening agent: an approach to clinically augment the therapeutic efficacy for melasma treatment, *Drug Delivery*, 29:1, 1212-1231.
15. Khalil, R.M., El-Bary, A.A., Kassem, M.A., Ghorab, M.M., & Ahmed, M. (2013). Solid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterization. *European Scientific Journal*, 9(21);779-98.
16. B.Ramu et al, Formulation Of Lamotrigine Orodispersible Tablets By Using New Generation Superdisintegrants *World Journal Of Pharmacy And Pharmaceutical Sciences* Volume 4,2015, Issue 06, 631- 643.
17. Ramu B, Sathish Kumar M, Ramakrishna M (2015) Current Regulatory Scenario for Conducting Clinical Trials in India. *Pharmaceut Reg Affairs*. 4:137. doi: 10.4172/2167-7689.1000140.
18. Mounika, I y Ramu, B. 2018. “Lifestyle drugs: concept and impact on society.” *Journal of Human Virology & Retrovirology*, 6(2): 46-49. <https://doi.org/10.15406/jhvr.2018.06.00194>.
19. Ramu B, Saibaba SV. Role of community pharmacist in management of anaemia. *Pharm Pharmacol Int J.*, 2018; 6(3): 216–220. DOI: 10.15406/ppij.2018.06.00178.